Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Robust isolation of malignant plasma cells in multiple myeloma.

Frigyesi, Ildiko LU ; Adolfsson, Jörgen LU ; Ali, Mina LU ; Christophersen, Mikael Kronborg LU ; Johnsson, Ellinor LU ; Turesson, Ingemar LU ; Gullberg, Urban LU ; Hansson, Markus LU orcid and Nilsson, Björn LU (2014) In Blood 123(9). p.1336-1340
Abstract
Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable... (More)
Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
123
issue
9
pages
1336 - 1340
publisher
American Society of Hematology
external identifiers
  • pmid:24385542
  • wos:000335839300016
  • scopus:84899692195
  • pmid:24385542
ISSN
1528-0020
DOI
10.1182/blood-2013-09-529800
project
Genetic predisposition for multiple myeloma
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Clinical Genetics (013022003), Emergency medicine/Medicine/Surgery (013240200), Division of Hematology and Transfusion Medicine (013041100)
id
c3e71216-e4d1-436a-8943-862eed761439 (old id 4292197)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24385542?dopt=Abstract
date added to LUP
2016-04-01 10:14:21
date last changed
2022-05-05 19:59:14
@article{c3e71216-e4d1-436a-8943-862eed761439,
  abstract     = {{Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.}},
  author       = {{Frigyesi, Ildiko and Adolfsson, Jörgen and Ali, Mina and Christophersen, Mikael Kronborg and Johnsson, Ellinor and Turesson, Ingemar and Gullberg, Urban and Hansson, Markus and Nilsson, Björn}},
  issn         = {{1528-0020}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{1336--1340}},
  publisher    = {{American Society of Hematology}},
  series       = {{Blood}},
  title        = {{Robust isolation of malignant plasma cells in multiple myeloma.}},
  url          = {{http://dx.doi.org/10.1182/blood-2013-09-529800}},
  doi          = {{10.1182/blood-2013-09-529800}},
  volume       = {{123}},
  year         = {{2014}},
}